Curium Announces Definitive Agreement to Merge with Lantheus
Summary
BOSTON and BEDFORD, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Curium™, a leading, global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceuticals that improve the way cancer is diagnosed and treated, and Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), today announced that Curium US Holdings LLC (“Curium US”) and Lantheu
Why It Matters
This announcement reflects ongoing developments in the technology sector that may impact enterprise IT strategy, consumer technology adoption, or industry competitive dynamics.
Note
This summary is generated using AI analysis of the original press release. Always refer to the original source for complete details.